A Reliable and Reproducible Test for Adequate Glucose Counterregulation in Type I Diabetes Mellitus

  1. P Brunetti
  1. Istituto di Patologia Medica, Università di Perugia Perugia, Italy Diabetes and Metabolism Research Laboratory, Endocrine Research Unit, Mayo Clinic and Medical School Rochester, Minnesota
  1. Address reprint requests to Geremia B. Bolli, M. D., Istituto Patologia Medica dell'Università, Via Enrico dal Pozzo, 06100 Perugia, Italy.


The safety, reproducibility, and reliability of an insulin infusion test for assessment of adequate glucose counterregulation were evaluated in 18 patients with type I (insulin-dependent) diabetes mellitus. When the test (a 60-min, 30-mU/m2/min insulin infusion) was administered on three separate occasions at 3–4-wk intervals, coefficients of variation for plasma glucose and counterregulatory hormone (glucagon, epinephrine, cortisol, and growth hormone) responses averaged less than 8%. No patient experienced symptoms requiring discontinuation of the test and plasma glucose concentrations increased spontaneously after stopping the insulin infusion. Using objective criteria based on plasma glucose nadirs or postnadir rates of plasma glucose recovery, no patient judged to have adequate glucose counterregulation by the test (post-nadir rates of plasma glucose recovery or plasma glucose nadir above 0.4 mg/dl/min and 45 mg/dl) developed severe hypoglycemia (plasma glucose < 40 mg/dl) during up to 7 mo of intensive insulin therapy, whereas nearly all patients with inadequate counter-regulation did. We conclude that this test, when performed in standardized conditions, is safe and reproducible and can reliably predict those patients with type I diabetes who are at risk of developing severe hypoglycemia during intensive insulin therapy.

  • Received November 18, 1983.
| Table of Contents